Development of Ultrafine Particles for Intranasal Delivery of Antipsychotics

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41MH098521-01
Agency Tracking Number: R41MH098521
Amount: $296,413.00
Phase: Phase I
Program: STTR
Awards Year: 2012
Solicitation Year: 2012
Solicitation Topic Code: NIMH
Solicitation Number: PA11-133
Small Business Information
4701 INNOVATION DRIVE, LINCOLN, NE, -
DUNS: 131068186
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: Y
Principal Investigator
 SANDRA NORIEGA
 (402) 416-1811
 sandraneb@yahoo.com
Business Contact
 GUSTAVO LARSEN
Phone: (402) 416-1811
Email: LNKChemsolutions@netscape.net
Research Institution
 UNIVERSITY OF CHICAGO
 UNIVERSITY OF CHICAGO
5801 S ELLIS AVE
CHICAGO, IL, 60637-
 () -
 Nonprofit college or university
Abstract
DESCRIPTION: The goal of the proposed project is to develop a biocompatible ultrafine particle-based vector system for the intranasal delivery of clozapine for the pharmacological therapy of treatment- resistant schizophrenic disorders and their associatedsuicidal behavior. The rationale behind the use of intranasal clozapine is grounded on the observation of clozapine's extensive first- pass metabolism associated with buccal intake, clozapine's extensive binding to plasma proteins, its short elimination half-life, the absence of significantly active metabolites, and the potentially serious side effects brought about by the high oral doses required for therapeutic benefit. The LNK Chemsolutions LLC/University of Chicago team will use a series of particle design tools, in vivo, ex vivo and in vitro methods to develop the seminal Phase-I level research. Electrohydrodynamic methods will be used to design particles with well-defined sizes and drug payloads, using three different polymers. In vitro drug releaseexaminations will be complemented by muco-adhesive tests, and ex vivo (swine nasal membrane) drug permeation studies. These will guide in vivo (mouse model) studies aimed at elucidating particle and drug transport. PUBLIC HEALTH RELEVANCE: In this SBIR Phase I grant application, LNK Chemsolutions LLC and the University of Chicago researchers are partnering to develop an intranasal drug delivery platform for one anti-psychotic drug. In vitro and in vivo studies will be performed to investigate the potential of the proposed approach.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government